Literature DB >> 23259427

Current status of sentinel lymph node mapping in the management of endometrial cancer.

Helena Robova1, Lukas Rob, Michael Jiri Halaska, Marek Pluta, Petr Skapa.   

Abstract

The prognosis of endometrial cancer (EC) is generally favorable, while lymph node status remains the most important prognostic factor. Sentinel lymph node mapping (SLNM) could help to find women in whom adjuvant therapy could be omitted. This review analyzes different techniques of injection and histopathologic elaboration of SLNM in EC. Results of studies on SLNM in ECs seem to be promising, but only a small series have been published so far. The studies are subdivided into three groups by the technique of injection (hysteroscopic, subserosal and cervical). Range of detection rate for SLNM varies from 45 to 100%. Hysteroscopic injection is not easy to learn; moreover, exact peritumoral injection in large tumors is often impossible. Subserosal administration of tracer is difficult during laparoscopic or robotic surgery. Cervical injection is quite a controversial technique because distribution of SLNs in ECs is different from cervical cancer; moreover, there is no large study using cervical injection with systematic pelvic and para-aortic lymphadenectomy.

Entities:  

Mesh:

Year:  2013        PMID: 23259427     DOI: 10.1586/era.12.157

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

Review 1.  Sentinel lymph node in endometrial cancer: a review.

Authors:  Cyril Touboul; Enrica Bentivegna; Catherine Uzan; Sebastien Gouy; Patricia Pautier; Catherine Lhommé; Pierre Duvillard; Christine Haie-Meder; Philippe Morice
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 2.  Application of sentinel nodes in gynaecological cancer therapy.

Authors:  M H M Oonk; A G J van der Zee
Journal:  EJC Suppl       Date:  2013-09

3.  Sentinel lymph node mapping in gynecological oncology.

Authors:  Jiang Du; Yaling Li; Qing Wang; Nasra Batchu; Junkai Zou; Chao Sun; Shulan Lv; Qing Song; Qiling Li
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.